Mobile

A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001719-77

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to compare overall survival of subjects treated with tipifarnib with that of subjects treated with best supportive care including hydroxyurea.

Critère d'inclusion

  • Treatment of Acute Myeloid Leukemia (AML)

Liens